WESTMINSTER, Colo., USA (June 1, 2011) – Surefire Medical Inc., a Colorado- based medical device company, announced today the appointment of Mark Lupa, Ph.D. and Ginger L. Graham to the Board of Directors.

Mark Lupa founded the Tabernash Brewing Company in 1993 and served as the CEO and CFO. In 1998, Tabernash Brewing Company merged with Left Hand Brewing. Lupa is currently Managing Director of High Country Venture, a venture capital fund in Boulder, Colorado, and has served as founding member of the Board of Directors of Taligen Therapeutics, Sierra Neuropharma, Oberon, DCS Surgical, and Theratogs.

With more than 30 years of experience in the biopharmaceutical and medical device industries, Ginger Graham is the former President and Chief Executive Officer of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on diabetes and obesity.

Prior to her time at Amylin, she was Group Chairman, Office of the President for Guidant Corporation, a major cardiovascular medical device manufacturer based in Indianapolis, IN. Graham also serves on the Boards of Directors for Walgreen Co., Genomic Health, Inc., Proteus Biomedical, and the American Diabetes Association Research Foundation, where she serves as Vice Chair.

“Surefire Medical is pleased to welcome Mark and Ginger to our Board of Directors and look forward to working with both of them to achieve our strategic, regulatory, sales and financial objectives,” said Jim Chomas, co-founder and CEO of Surefire Medical. “Both Mark and Ginger bring a wealth of leadership experience to our board and will be instrumental in the success of our business in the medical device marketplace.”

While Graham and Lupa are joining Surefire’s Board of Directors, Dr. Aravind Arepally will step down from his current board position and will continue to maintain Observer rights as the Chairman of the Scientific Advisory Board.

Achievement

Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.